AmoxiHub welcomes feedback about the accuracy, clarity and usefulness of our U.S.-focused information on amoxicillin, amoxicillin/clavulanate (Augmentin), and responsible antibiotic use. Use this page to report a factual concern, flag an outdated product or regulatory reference, suggest a credible source, or ask about our editorial approach. This contact channel is for website-related communication, not personal medical advice or prescription requests.
Use the form below for questions or feedback related to AmoxiHub. Providing the exact URL, the heading or passage concerned, and a short description of the issue helps identify the content that may require clarification or further research.
For medical, safety or product-information corrections, you can optionally include an FDA label, DailyMed record, CDC recommendation, FDA approval record, insurer document or another directly relevant reference. We consider the evidence provided, but submitting a source does not guarantee that a page will be changed.
We aim to distinguish the evidence supporting statements about amoxicillin from evidence about amoxicillin/clavulanate. If you believe a claim is inaccurate, please identify the page, quote the specific statement and explain whether the concern involves the active ingredients, dosage form, clinical context, safety information or U.S. regulatory status.
Helpful references include current FDA prescribing information, DailyMed labeling, FDA Orange Book approval records, CDC antibiotic-use guidance, MedlinePlus, and appropriately sourced clinical publications. A product label should be matched to the exact medicine and formulation discussed, rather than treated as evidence for every related antibiotic.
U.S. amoxicillin and Augmentin product records can change independently across brands, generic applications, dosage forms, manufacturers, labelers and NDC listings. If a product guide is outdated, please identify the exact product, both ingredient strengths where applicable, the dosage form and the source that documents the change.
This matters particularly for amoxicillin/clavulanate. A single-ingredient amoxicillin tablet differs from a two-ingredient Augmentin tablet; standard Augmentin, Augmentin ES-600 suspension and Augmentin XR also have distinct labeling and formulation characteristics. FDA approval, NDC listing and current pharmacy inventory should not be treated as the same type of evidence.
Readers are welcome to suggest sources that improve an article's accuracy or context. Depending on the question, useful references may include FDA-approved prescribing information, DailyMed, the FDA Orange Book, the National Drug Code Directory, CDC clinical guidance, MedlinePlus, Medicare, HealthCare.gov, or peer-reviewed medical research.
A source is evaluated for its relevance to the exact claim, population, formulation and U.S. regulatory context. For example, a drug's approved indications do not establish that it is suitable for a particular patient, while a pharmacy listing does not establish FDA approval, a guaranteed price or current availability.
Questions about how AmoxiHub researches and structures its content are welcome. Our principles for sourcing, distinguishing medical claims from commercial information, and correcting errors are described in the Editorial Policy. See our Medical Review page for the standards and limitations associated with clinical review.
Our Medical Reviewer page explains what qualifications, responsibilities and disclosures are relevant to medical oversight. Describing a review framework does not mean that every article has been independently reviewed by a licensed clinician; any such review should be documented accurately on the relevant page.
AmoxiHub is an independent informational website. We are not a pharmacy, telehealth provider, clinic or prescribing service, and we cannot diagnose illness, determine whether an antibiotic is indicated, authorize a prescription or select a treatment through this form.
Questions about suspected infections, penicillin allergy, side effects, interactions, pregnancy, kidney or liver conditions, dose, treatment duration or whether amoxicillin or Augmentin is suitable for you should be discussed with a qualified healthcare professional. A paid consultation does not guarantee that an antibiotic will be prescribed.
For an emergency or signs of a severe allergic reaction, such as difficulty breathing or swelling of the face or throat, seek emergency medical assistance immediately rather than waiting for a response to a website message.
Do not include medical records, prescription images, laboratory results, diagnosis histories, insurance or payment details, identification numbers, or other sensitive personal health information in this form. We do not need those details to investigate an editorial or technical issue.
General information about website data handling is available in the Privacy Policy. Avoid entering information that you would not want to provide through a general website feedback channel.
A specific report is easier to evaluate than a general disagreement. When possible, include the affected URL, the exact statement, what you believe is inaccurate and a primary source that supports the correction. Do not send patient information to substantiate the report.
| Helpful information | Why it helps |
|---|---|
| Page URL | Identifies the exact article that should be reviewed. |
| Specific statement or section | Helps distinguish the disputed claim from the rest of the page. |
| Reason for the correction | Explains whether the concern involves accuracy, wording, context or outdated information. |
| Authoritative source | Allows the editorial evidence to be compared directly. |
| Exact product, formulation and market | Prevents evidence about plain amoxicillin, Augmentin, ES-600, XR or another market from being misapplied. |
Questions are assessed according to the nature of the concern and the supporting evidence. Correcting a broken source link or unclear term differs from reviewing a claim about contraindications, drug interactions, antimicrobial stewardship, product approval, formulation equivalence or insurance coverage.
Where medical meaning or patient safety may be affected, additional comparison with official labeling or current clinical guidance may be appropriate. Any medical-review claim should reflect actual reviewer involvement rather than an assumed approval. We cannot guarantee an edit or an individual response to every submission.
AmoxiHub discusses prescription products, pharmaceutical manufacturers, pharmacies, clinicians, telehealth access, discount programs and insurance as informational topics. Contacting the website does not guarantee editorial coverage of a product or company, approval of a promotional claim, a prescription, pharmacy stock or a commercial partnership.
Product identity, safety and medical explanations should remain independent of commercial representations. Any proposed factual correction should be supported by appropriate evidence; material submitted by a business may require additional verification and disclosure before inclusion.
Use of this contact page and AmoxiHub is subject to the site's Terms of Use. Read our About AmoxiHub page for the site's mission, coverage and educational limitations.